AD Sigma-1 Receptor & Molecular Chaperone Therapy Companies

Migration, Crosslink

📖

AD Sigma-1 Receptor & Molecular Chaperone Therapy Companies

active

wiki page Created: 2026-04-02T07:20:07 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-companies-ad-sigma-1-receptor-chape

📖 Wiki Page

company948 wordssynced 2026-04-02

Alzheimer's Disease Sigma-1 Receptor & Molecular Chaperone Therapy Companies

Overview

flowchart TD companies_ad_sigma_1_receptor_["AD Sigma-1 Receptor and Molecular Chaperone Ther"] style companies_ad_sigma_1_receptor_ fill:#4fc3f7,stroke:#333,color:#000 companies_ad_sigma_1_0["Sigma-1 Receptor Agonists"] companies_ad_sigma_1_receptor_ -->|"includes"| companies_ad_sigma_1_0 style companies_ad_sigma_1_0 fill:#81c784,stroke:#333,color:#000 companies_ad_sigma_1_1["Pridopidine DNL458"] companies_ad_sigma_1_receptor_ -->|"includes"| companies_ad_sigma_1_1 style companies_ad_sigma_1_1 fill:#ef5350,stroke:#333,color:#000 companies_ad_sigma_1_2["Astellas Pharma"] companies_ad_sigma_1_receptor_ -->|"includes"| companies_ad_sigma_1_2 style companies_ad_sigma_1_2 fill:#ffd54f,stroke:#333,color:#000 companies_ad_sigma_1_3["Relmada Therapeutics"] companies_ad_sigma_1_receptor_ -->|"includes"| companies_ad_sigma_1_3 style companies_ad_sigma_1_3 fill:#ce93d8,stroke:#333,color:#000 companies_ad_sigma_1_4["NeuroSearch A/S"] companies_ad_sigma_1_receptor_ -->|"includes"| companies_ad_sigma_1_4 style companies_ad_sigma_1_4 fill:#4fc3f7,stroke:#333,color:#000 companies_ad_sigma_1_5["AlgoTherapeutics"] companies_ad_sigma_1_receptor_ -->|"includes"| companies_ad_sigma_1_5 style companies_ad_sigma_1_5 fill:#81c784,stroke:#333,color:#000

...

Alzheimer's Disease Sigma-1 Receptor & Molecular Chaperone Therapy Companies

Overview

Mermaid diagram (expand to render)

Sigma-1 Receptor (S1R) modulators and Molecular Chaperone therapies represent two complementary emerging approaches to Alzheimer's disease treatment that target fundamental cellular processes: endoplasmic reticulum (ER) stress, protein homeostasis, calcium dysregulation, and mitochondrial dysfunction.

Sigma-1 Receptor: The Sigma-1 Receptor is a unique chaperone protein localized to the ER membrane at mitochondria-associated membranes (MAMs). It serves as a calcium sensor and master regulator of cellular stress responses. S1R activation has been shown to protect against ER stress, maintain calcium homeostasis, improve mitochondrial function, and reduce neuroinflammation—all processes implicated in AD pathogenesis["@maurice2009"][@cai2020].

Molecular Chaperones: Heat shock proteins (Hsp90, Hsp70) and small molecule chaperones help maintain protein folding homeostasis. In AD, the accumulation of misfolded Abeta and tau overwhelms the cellular protein quality control system. Chaperone-based therapies aim to enhance this system to clear toxic protein aggregates.

This category page catalogs companies developing these approaches specifically for Alzheimer's disease.

Sigma-1 Receptor Agonists

Pridopidine (DNL458)

Developer: [Denki Kagaku Kogyo (Denka)](https://www.denka.co.jp/) (Japan)

| Attribute | Details |
|-----------|---------|
| Focus | Sigma-1 receptor agonist, dopaminergic stabilization |
| Lead Candidate | Pridopidine (DNL458) |
| Indication | Alzheimer's disease, Huntington's disease |
| Stage | Phase 2 (AD), Phase 3 (HD) |
| Mechanism | S1R agonist with D2 receptor modulation |

Scientific Rationale: Pridopidine has high affinity for Sigma-1 receptors and shows neuroprotective effects through:

ER stress reduction
Mitochondrial function improvement
Calcium homeostasis restoration
Anti-inflammatory effects in microglia

Clinical Status: Pridopidine has completed Phase 3 trials for Huntington's disease (PRIDE-HD) with favorable safety data. A Phase 2 trial in AD is planned to assess cognitive benefits via S1R activation[@nguyen2023].

Astellas Pharma

Website: [Astellas](https://www.astellas.com/)

| Attribute | Details |
|-----------|---------|
| Focus | Multiple CNS targets including S1R |
| Lead Candidates | Various S1R modulators |
| Indication | Alzheimer's disease, Parkinson's disease |
| Stage | Discovery/Preclinical |
| Mechanism | Selective Sigma-1 receptor agonists |

Notes: Astellas has developed multiple Sigma-1 receptor modulators including ATA-221 (for PD) and continues to explore S1R targets for neurodegenerative diseases.

Relmada Therapeutics

Website: [Relmada Therapeutics](https://www.relmada.com/)

| Attribute | Details |
|-----------|---------|
| Focus | CNS drug development |
| Lead Candidate | REL-1017 (Esmethadone) |
| Indication | Major depressive disorder (not AD-specific) |
| Stage | Phase 3 |
| Mechanism | NMDA antagonist (not S1R-focused) |

Notes: While Relmada's lead candidate targets NMDA pathways, the company has explored CNS mechanisms relevant to neurodegeneration.

NeuroSearch A/S

Notes: Original developer of pridopidine, which was outlicensed to Denki/Denka for continued development.

AlgoTherapeutics

Notes: Emerging company focused on Sigma-1 receptor modulators for CNS disorders.

Molecular Chaperone Approaches

Hsp90 Inhibitors

Hsp90 inhibitors shift the protein folding equilibrium toward Hsp70, enhancing degradation of misfolded proteins.

| Company | Candidate | Stage | Notes |
|---------|-----------|-------|-------|
| Biohaven Pharmaceutical | Multiple Hsp90 inhibitors | Discovery | Exploring CNS applications |
| Synta Oncology (acquired) | Ganetespib (STA-9090) | Discontinued | Originally for cancer, explored in neurodegeneration |

Hsp70 Inducers

| Company | Candidate | Stage | Notes |
|---------|-----------|-------|-------|
| Retro Biosciences | RB-001 | Phase 1 | Senolytic + chaperone approach for aging |
| Calico (Alphabet) | Various | Discovery | Aging biology focus |

Small Molecule Chaperones

| Company | Candidate | Stage | Notes |
|---------|-----------|-------|-------|
| Trehalose developers | Trehalose | Preclinical | Sugar molecule with chaperone activity |
| TUDCA (Tauroursodeoxycholic acid) | Various | Phase 2/3 | Bile acid with protein stabilization properties |

Proteostasis Therapeutics

Website: [Proteostasis Therapeutics](https://www.proteostasis.com/)

| Attribute | Details |
|-----------|---------|
| Focus | Protein homeostasis modulation |
| Platform | UPRmt (mitochondrial unfolded protein response) modulators |
| Stage | Discovery/Preclinical |
| Mechanism | Small molecules enhancing cellular protein quality control |

Hsp90-Targeted Approaches

Companies exploring Hsp90 inhibition for neurodegenerative diseases:

Targeting client proteins including tau, Aβ, α-synuclein
Brain-penetrant inhibitors in development
Combination with Hsp70 inducers

Scientific Rationale for AD

Sigma-1 Receptor in AD Pathogenesis

ER Stress: AD neurons exhibit chronic ER stress due to Aβ and tau accumulation. S1R activation enhances ER chaperone activity (BiP/GRP78) and reduces the unfolded protein response[@cai2020].

Calcium Dysregulation: S1R at MAMs regulates calcium transfer between ER and mitochondria. S1R agonists help restore calcium homeostasis disrupted in AD.

Mitochondrial Dysfunction: S1R activation improves mitochondrial function, reduces ROS, and supports neuronal energy metabolism.

Neuroinflammation: S1R modulation reduces microglial activation and pro-inflammatory cytokine release.

Synaptic Protection: S1R activation supports dendritic spine density and synaptic plasticity.

Molecular Chaperones in AD

Aβ Aggregation: Hsp70/Hsp90 can prevent Aβ oligomerization and promote clearance

Tau Pathology: Chaperone modulation reduces tau phosphorylation and aggregation

Proteostasis Restoration: Enhancing the cellular protein quality control system

Pipeline Summary

| Approach | Companies | Stage | Promise |
|----------|-----------|-------|---------|
| S1R Agonists | Denka, Astellas, others | Phase 2-3 | High (proven safety in HD) |
| Hsp90 Inhibitors | Various | Discovery/Preclinical | Moderate |
| Hsp70 Inducers | Retro Biosciences, Calico | Phase 1/Discovery | Moderate-High |
| Small Molecule Chaperones | Various academic/industry | Preclinical | Moderate |

[Sigma-1 Receptor Agonists](/therapeutics/sigma-1-receptor-agonists) — Detailed mechanism and compounds
[Molecular Chaperone Therapy](/therapeutics/molecular-chaperone-therapy) — Chaperone biology and therapeutic approaches
[Sigma1 Receptor Protein](/proteins/sigma1r-protein) — Protein structure and biology
[ER Stress in Neurodegeneration](/mechanisms/er-stress-neurodegeneration) — Pathway details
[Protein Homeostasis](/mechanisms/protein-homeostasis) — Proteostasis mechanisms

References

[Maurice, T. & Su, T.P. The pharmacology of sigma-1 receptors (2009)](https://doi.org/10.1016/j.pharmthera.2009.01.001)

[Cai, J. et al. Sigma-1 receptor protects against endoplasmic reticulum stress in Alzheimer's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32895526/)

[Nguyen, L. et al. Targeting Sigma-1 Receptor for Neurodegenerative Disease Treatment (2023)](https://pubmed.ncbi.nlm.nih.gov/37054218/)

[Golipur, A. et al. Molecular chaperone-based therapeutics for neurodegenerative diseases (2023)](https://pubmed.ncbi.nlm.nih.gov/36745678/)

📖 View canonical wiki page →

Related Entities

companies-ad-sigma-1-receptor-chaperone-therapy-companies

▸Metadataorigin_type: v1_polymorphic_backfill

slug	companies-ad-sigma-1-receptor-chaperone-therapy-companies
kg_node_id	None
entity_type	company
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-5d0aa5399741
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'companies-ad-sigma-1-receptor-chaperone-therapy-companies'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

47

Outgoing

47

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

AD Sigma-1 Receptor & Molecular Chaperone Therapy Companies

Alzheimer's Disease Sigma-1 Receptor & Molecular Chaperone Therapy Companies

Overview

Alzheimer's Disease Sigma-1 Receptor & Molecular Chaperone Therapy Companies

Overview

Sigma-1 Receptor Agonists

Pridopidine (DNL458)

Astellas Pharma

Relmada Therapeutics

NeuroSearch A/S

AlgoTherapeutics

Molecular Chaperone Approaches

Hsp90 Inhibitors

Hsp70 Inducers

Small Molecule Chaperones

Proteostasis Therapeutics

Hsp90-Targeted Approaches

Scientific Rationale for AD

Sigma-1 Receptor in AD Pathogenesis

Molecular Chaperones in AD

Pipeline Summary

References

💬 Discussion

📗 Cite This Artifact

AD Sigma-1 Receptor & Molecular Chaperone Therapy Companies

Alzheimer's Disease Sigma-1 Receptor & Molecular Chaperone Therapy Companies

Overview

Alzheimer's Disease Sigma-1 Receptor & Molecular Chaperone Therapy Companies

Overview

Sigma-1 Receptor Agonists

Pridopidine (DNL458)

Astellas Pharma

Relmada Therapeutics

NeuroSearch A/S

AlgoTherapeutics

Molecular Chaperone Approaches

Hsp90 Inhibitors

Hsp70 Inducers

Small Molecule Chaperones

Proteostasis Therapeutics

Hsp90-Targeted Approaches

Scientific Rationale for AD

Sigma-1 Receptor in AD Pathogenesis

Molecular Chaperones in AD

Pipeline Summary

Related Pages

References

💬 Discussion